Loading...
XNASCLDX
Market cap1.62bUSD
Jan 10, Last price  
24.35USD
1D
-8.22%
1Q
-22.25%
Jan 2017
587.85%
Name

Celldex Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CLDX chart
P/E
—
P/S
234.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
35.93%
Rev. gr., 5y
-6.32%
Revenues
7m
+192.02%
6,858,6003,088,3414,931,0975,102,9307,455,50715,180,00046,793,0009,265,00011,202,0004,111,0003,586,0005,480,0006,786,00012,743,0009,538,0003,573,0007,418,0004,651,0002,357,0006,883,000
Net income
-141m
L+15.19%
-13,203,700-18,096,569-20,373,932-21,638,761-47,500,571-36,525,000-2,533,000-44,799,000-59,123,000-81,550,000-118,080,000-127,197,000-128,530,000-93,031,000-151,184,000-50,372,000-59,780,000-70,511,000-122,783,000-141,429,000
CFO
-107m
L+3.43%
-10,347,900-6,016,63027,000,319-19,302,98618,280,766-29,869,000-30,372,000-35,658,000-49,782,000-67,669,000-101,537,000-98,887,000-113,036,000-99,931,000-75,235,000-46,415,000-40,404,000-60,909,000-103,732,000-107,291,000
Earnings
Feb 24, 2025

Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
URL
https://celldex.com/
IPO date
May 15, 1986
Employees
148
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,883
192.02%
2,357
-49.32%
Cost of revenue
151,933
110,853
Unusual Expense (Income)
NOPBT
(145,050)
(108,496)
NOPBT Margin
Operating Taxes
10,458
Tax Rate
NOPAT
(145,050)
(118,954)
Net income
(141,429)
15.19%
(122,783)
74.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
216,222
4,076
BB yield
-11.25%
-0.20%
Debt
Debt current
3,228
1,445
Long-term debt
3,470
6,621
Deferred revenue
Other long-term liabilities
4,403
5,333
Net debt
(416,900)
(296,886)
Cash flow
Cash from operating activities
(107,291)
(103,732)
CAPEX
(1,818)
(1,828)
Cash from investing activities
(105,782)
89,942
Cash from financing activities
218,458
4,076
FCF
(147,940)
(119,150)
Balance
Cash
423,598
304,952
Long term investments
Excess cash
423,254
304,834
Stockholders' equity
(1,393,997)
(1,254,625)
Invested Capital
1,831,727
1,590,195
ROIC
ROCE
EV
Common stock shares outstanding
48,449
46,888
Price
39.66
-11.02%
44.57
15.35%
Market cap
1,921,487
-8.05%
2,089,798
26.16%
EV
1,504,587
1,792,912
EBITDA
(142,042)
(105,600)
EV/EBITDA
Interest
2,909
Interest/NOPBT